Wegovy is a prescription drug created by Novo Nordisk for chronic weight management in adults with obesity or overweight who have at least one weight-related condition. Its active ingredient, semaglutide, is a GLP-1 receptor agonist that helps regulate appetite and food intake. Approved by the FDA in 2021, Wegovy is part of a growing class of medications targeting metabolic health and weight loss, and has been widely discussed in both medical and investment circles due to its commercial success and demand.